March 10 (Reuters) - Mineralys Therapeutics ( MLYS )
said on Monday its blood pressure drug, lorundrostat, met the
main goal in late- and mid- stage trials.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj
Kalluvila)